weakness on walking, standing or even sitting unsupported. She also described a persistent low grade fever for 1 month and new onset diabetes for last 6 months with having no history of hypertension or bronchial asthma.
On examination, there were marked erythematous rashes more noticeable on face and over the knee joint areas without joint involvement and there was periorbital puffiness. Temperature varied from 100-101 o F throughout the period of hospital admission having no definite pattern. Other vitals were normal. Deep tendon reflexes were difficult to elicit and there's marked degree of muscle tenderness on palpation.
Laboratory investigations revealed dimorphic anaemia with lymphopenia with a raised ESR (115 mm in 1 st hour), markedly elevated muscle enzymes (CPK-17614 u/l), ANA negative, Anti-DsDNA negative, ENA profile negative, serum ferritin-4621ugm/L, blood culture report was unremarkable and x-ray skull, x-ray chest and ultrasonogram of abdomen were found normal. Serum basal cortisol, blood urea, serum creatinine, serum calcium were normal and HBsAg, Anti-HCV, VDRL, TPHA were negative.
Finally, muscle biopsy was done and histopathology showed perifascicular atropy, infiltration of inflammatory cells along with necrotic and regenerated muscle fibres with no inclusion bodies suggestive of inflammatory myopathy compatible with dermatomyositis.
Treatment was started with prednisolone 1 mg/ kg body weight along with omeprazole, calcium supplement and indomethacin and there was a substantial improvement in next 10 days. She was then discharged with a follow up advice after 3 months.
On the first follow up, patient could sit unsupported but yet to walking and standing alone. Her skin rashes and muscle pain was reduced, fever subsided and general condition improved.
On subsequent follow up at 6 months of starting treatment, the patient again complaint of significant muscle pain and was unable to sit unsupported. Muscle biopsy was done again and histopathology showed type-2 fibre atropy. A diagnosis of steroid induced myopathy with dermatomyositis was confirmed and methotrexate was started at 10 mg weekly with folic acid and gradual tapering of steroid.
Discussion
Dermatomyositis (DM) is a form of idiopathic inflammatory myopathy that involves skeletal muscle and skin characterized by the appearance of progressive muscle weakness and inflammation 1 . It is potentially life threatening that affecting individuals of all ages .The estimated incidence of DM has been calculated as 9.63 per 1 million persons, with a prevalence of 21.42 per 100,000 persons .The etiology of dermatomyositis remains unknown; some studies have reported an association with histocompatability antigens, environmental agents (e.g., virus, drugs) and autoimmunity 2 . The average age at diagnosis is 40, and almost twice as many women are affected as men 3 .
Classification:
Dermatomyositis has been classified in different ways. A practical approach is to divide it into adult-onset and juvenile-onset each being further divided into subgroups: The muscle involvement is typically defined as slowly progressive, symmetrical proximal muscle weakness in the presence of elevated muscle derived enzymes, abnormal muscle biopsy with MRI or electromyelogram (EMG). Patients complain of fatigue of muscles or weakness while climbing stairs. There is also difficulty in rising from sitting position, combing hair and reaching for items above the shoulders. Muscle tenderness is a variable finding. Testing of muscle strength is part of assessment of these patients. Extensor muscles are more affected than flexors. Distal strength is almost always maintained 7, 8 .
Adult onset
Cutaneous features may present simultaneously or may follow or preceed muscle involvent. It includes pathognomic changes of heliotrope rashes and gottron's papule as well as characteristics photosensitive erythema, non-scarring alopecia with or without scaly poikilodermatous changes and subungual or cuticular changes 9 . Systemic features of dermatomyositis include arthralgia, arthritis, dyspnea, dysphagia, dysphonia, arrhythmias, abdominal pain and visual changes 9 .
Diagnostic criteria for dermatomyositis: Patients presenting with at least 1 finding from the above three and 4 findings from features 2-9 are said to have dermatomyositis 10, 11 .
Complications of dermatomyositis include contracted limbs, aspiration pneumonia, type II respiratory failure, diffuse interstitial pneumonitis, pulmonary fibrosis, pericarditis, cardiac failure, cardiomyopathy, cardiac conduction defects, vasculitis, large bowel infarction (secondary to vasculopathy), muscle atrophy, muscle calcification, malnutrition, acute kidney failure, malignancy, Raynaud's phenomenon, hypertrichosis and sclerosis of skin. Ocular complications include nystagmus, cotton-wool spots, optic atrophy and conjunctival edema 10, 11 .
Dermatomyositis precedes the neoplasm in 40% cases, may present simultaneously in 26% cases and neoplasm may occur first in 34% cases. Primary tumour occurs in lungs, breast, female genital tract, stomach, rectum, kidney or testis 12 .
Investigations:
Laboratory investigations is pivotal for confirmation of a diagnosis of dermatomyositis along with pertinent clinical components as elevated muscle enzyme and characteristic histopathologic findings are important part of diagnosis, e. g.
1.
Muscle enzyme elevation (CPK, serum aldolase, LDH, ALT, AST, carbonic anhydrase isoenzyme II) 2. EMG: There is myopathic pattern, 10% are false-negative.
3. Muscle biopsy shows necrotic and regenerative muscle fibre with inflammatory cell infiltrate (Fig. 1 ) iii. Anti-EJ may be more associated with typical skin lesions.
ESR is elevated in approximately 50%
patients (does not correlate well with disease activity).
6. Rheumatoid factor seen in 20% patients, mostly in those with overlap syndrome.
7. von Willebrand factor reported to correlate with juvenile dermatomyositis.
8. Magnetic resonance imaging is useful for assessing the presence of an inflammatory myopathy in patients without weakness. Also useful in differentiating steroid myopathy from continued inflammation and may serve as a guide in selecting a muscle biopsy site 10 .
Treatment:
Prednisone remains the initial oral pharmacologic agent, given in a single daily dose of 0.5 to 1. Methotrexate is considered the first-line adjuvant therapy in patients who do not respond to prednisone. Oral therapy should be initiated at a dosage of 7.5 to 10 mg per week and increased by 2.5-mg increments until a goal of 25 mg per week is reached. Alternate intravenous dosing initiated at 10 mg per week should be increased by 2.5 mg per week until a total dosage of 0.5 to 0.8 mg per kg is reached.
It is important to also give 1 to 3 mg per day of folic acid to minimize the side effects of methotrexate 3, 13 .
Azathioprine, cyclosporine are suitable alternative or adjuvants in selected cases. Cyclophosphamide and IV immunoglobulin can be used in refractory cases. Other therapies include physical therapy, antihistamine for pruritus while thymectomy, plasmapheresis and ACTH gel are under trial 13 .
It is important to be aware of steroid myopathy which may mimic a worsening dermatomyositis. Differentiating steroid myopathy from worsening dermatomyositis is based on evaluation of neck flexor strength -neck flexor strength would be unchanged if steroid myopathy were developing. In these cases, methotrexate should be the choice where steroid should be gradually tapered and withdrawn 3 .
